The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.
Major events and milestones of the Company : 2002 - The Promoter established its API business - Established manufacturing plant at Kurkumbh, Maharashtra
2003 - First product registered with US-FDA - Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat
2004 - Commenced manufacturing at Mohol, Maharashtra
2008 - Ankleshwar plant at Gujarat inspected by US-FDA
2012 - Ankleshwar plant inspected by PMDA and AFSSAPS
2013 - Commenced manufacturing at Dahej, Gujarat - Ankleshwar plant inspected by COFEPRIS
2015 - Dahej plant inspected by US-FDA
2016 - Dahej plant inspected by PMDA Japan
2018 - Dahej plant inspected by EDQM, ANSM and US-FDA - Mohol plant inspected by US-FDA
2019 - The API business was spun off into the Company - Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan
2021 - Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally
2023
-The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore.
2025
-The Company name has changed from Glenmark Life Sciences Ltd to Alivus Life Sciences Ltd.
-The Company Informed regarding Agreement and Power Supply Agreement between Alivus Life Sciences Ltd. and Torrent Urja 19 Private Ltd.
|